Immunotherapy With Neo-adjuvant Chemotherapy for OVarian Cancer

NCT03249142 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

69

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancer

Interventions

DRUG: ARM A Durvalumab/chemotherapy association
DRUG: ARM B Durvalumab/Tremelimumab/chemotherapy association

Sponsor

ARCAGY/ GINECO GROUP

Collaborators

[object Object]